Pierre A Teulié | CEO
ODDIFACT

By showcasing untapped medical research to transform off-label usages into approved treatments, Pierre A Teulié is driving a new approach to facilitate the emergence of rare diseases' treatments. His strategic mindset and passion for making a difference have positioned him as a key player in the industry.

His role at ODDIFACT is to foster collaborations between industry stakeholders, research, regulatory bodies, and patient advocacy groups to accelerate the development and commercialization of orphan drugs.

Pierre is known for his ability to navigate complex regulatory landscapes and his strategic approach to business development. Under his guidance, ODDIFACT has established itself as a trusted partner for companies looking to bring orphan drugs to market, providing strategic insights and innovative solutions to overcome challenges in drug development.

As a speaker at World Orphan Drug Congress USA 2025, Pierre will share his expertise on orphan drug development, market access strategies, and the importance of collaboration in advancing rare disease treatments. His insights are sure to inspire and inform attendees, offering valuable perspectives on the future of orphan drugs and rare disease therapeutics.